Troubled Biotechs: Intercytex, Vanda, Advanced Life Sciences
This article was originally published in The Pink Sheet Daily
Executive Summary
With disappointing data from its lead program, the UK’s InterCytex is considering all options, including merger. In the U.S., Vanda is facing shareholder activism while Advanced Life Sciences is in the odd position of not being able to afford good news from FDA.
You may also be interested in...
Troubled Biotechs: Orexigen, Telik, Trubion
Vanda’s recent good news gives U.S. biotechs hope for a turnaround, while BIO’s Greenwood predicts most will survive the credit crunch.
Troubled Biotechs: Orexigen, Telik, Trubion
Vanda’s recent good news gives U.S. biotechs hope for a turnaround, while BIO’s Greenwood predicts most will survive the credit crunch.
Vanda’s Fanapt Approval Is FDA U-Turn
FDA’s “not approvable” letter for the atypical antipsychotic –only 10 months ago – requested comparative trials against Risperdal and Zyprexa. But approval came without that, although labeling sets up a difficult marketing task.